Bayer HealthCare

Bayer Healthcare

For many types of cancer classic chemotherapy is often the only form of treatment available. It functions on the basis of a cytotoxic effect – a cytotoxin kills cancer cells, halting tumor growth. However, these drugs also damage healthy cells and patients may, as a result, suffer severe side effects. With modern cancer therapies physicians are able to target the cancer more precisely.

They include the recently developed approach of antibody-drug conjugates (ADC). This new approach attacks the cancer in a much more targeted way and healthy cells are less severely affected.

Bayer HealthCare currently has several projects using this approach in its research pipeline. The company has the worldwide rights to utilize Seattle Genetics’ auristatin-based ADC technology with antibodies to several oncology targets.

MabPlex
Lonza
ADC Bio
 

6 West Belt
Wayne, NJ 07470
U.S.A

Web: Bayer HealthCare

Previous articleBaxter BioPharma Solutions
Next articleBioAgilytix Labs
ADC Review
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) launched in 2013, is designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, (basic, translational and clinical) research, clinicians/physicians, along with regulatory affairs, government authorities and representatives from payers, and policy makers. The Journal’s content includes peer reviewed research, commentaries, news features, discussions, editorials and blogs on topics relevant to a broad international readership. The Journal also offers a knowledge center (called ADC University) offering the latest and most relevant information about Antibody-drug Conjugates (ADCs), BiSpecific Antibodies, Site Specific Antibody Drug Conjugates, Small Molecule Drug Conjugates (SMDC), and Engineered Antibody Fragments. The purpose of the Journal is to present this information in an understandable and a useful format for all stakeholders.